News
Tru Niagen® Wins ‘Most Favourite Brand’ Award Among Watsons Hong Kong Loyalty Members
Tru Niagen® Recognized as MoneyBack Members' Most Favourite Brand at Health, Wellness & Beauty Awards 2019 of Watsons Hong KongLOS ANGELES, Oct. 31, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today its Tru Niagen® product was recognized as...
New Study Demonstrates a Unique Role of Nicotinamide Riboside Over Other NAD Precursors
LOS ANGELES, Oct. 17, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that the results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the...
ChromaDex Statement Regarding the October 9th Order in the Central District of California Litigation
LOS ANGELES, Oct. 11, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) issued the following statement. We would like to take this opportunity to comment on the latest order from the California court regarding the ongoing litigation with Elysium. This started as a breach of...
Humanitarian Grant Awarded for Preclinical Study on the Impact of NAD Precursor Vitamins on Milk Bioactive Production and Brain Development in Rodents
LOS ANGELES, Oct. 07, 2019 -- Dr. Charles Brenner, the Roy J. Carver Chair and Head of Biochemistry at the University of Iowa, receives a research grant from the Bill & Melinda Gates Foundation to study the effects of NAD-boosting supplements on the production of...
ChromaDex to Present at the 5th Annual B. Riley FBR Consumer and Media Conference
LOS ANGELES, Sept. 26, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 5th Annual B. Riley FBR Consumer and Media Conference at the Sofitel Hotel in New...
ChromaDex Announces $7 Million Private Placement of Common Stock
Private Placement Led By New Strategic Investors, Incremental to $10 Million Financing in May 2019LOS ANGELES, Aug. 14, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a securities purchase agreement for the sale of $7.0 million of its...
ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Authority (EFSA)
ChromaDex Achieves Milestone for Nicotinamide Riboside in EU Regulatory Process, Advances to European Commission for ReviewLOS ANGELES, Aug. 07, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) today announced that the European Food Safety Authority (EFSA) has issued a positive...
ChromaDex Corporation Reports Second Quarter 2019 Financial Results
Second Quarter 2019 Net Revenues Increased by 42% to $11.1 MillionSecond Quarter 2019 Highlights vs. Second Quarter 2018 Strong growth in net sales to $11.1 million, significantly higher gross margins, and improved marketing efficiency year-over-yearTRU NIAGEN net...
ChromaDex Adds Top Talent to its Leadership Team
Company Names Megan Jordan Chief Communications Officer, Dr. Andrew Shao Global Regulatory Lead, Alberto Bottene Head of Global SalesLOS ANGELES, Aug. 06, 2019 -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving...
ChromaDex to Report Second Quarter 2019 Financial Results on Wednesday, August 7, 2019
LOS ANGELES, July 31, 2019 -- ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed., August 7, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2019. The financial results will be...